Exclusive special offer and discount title banner vector image

RTX-GRT7039 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032

SCOPE OF THE REPORT

RTX-GRT7039 Osteoarthritis Drug Pipeline: 7 Major Market’s Analysis (Market Size of RTX-GRT7039 in the 7 Major Markets for Osteoarthritis) Country Analysis (Japan, Germany, United States, France, Italy, Spain, United Kingdom)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

RTX-GRT7039 (resiniferatoxin) is an investigational drug designed for pain relief in patients with knee osteoarthritis (OA). This highly potent agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor operates through a well-established mechanism and is administered directly into the joint via intra-articular injection. As osteoarthritis patients increasingly seek effective alternatives to traditional osteoarthritis treatments, RTX-GRT7039 offers a promising option. The drug is currently being assessed in a Phase III clinical trial to evaluate its effectiveness in treating osteoarthritis pain.

The drug is developed by Grünenthal GmbH, a pharmaceutical company specializing in pain management and related conditions, including peripheral neuropathic pain, chronic post-surgical pain, chronic low back pain, osteoarthritis, and migraine. Founded in 1946 by the Wirtz family in Stolberg, Germany, Grünenthal is headquartered in Aachen, Germany. The company operates in 27 countries across Europe, Latin America, and the United States, with its products distributed in approximately 100 countries globally. Grünenthal’s mission is to strive for a world without pain, reflecting its commitment to improving lives through innovative pain management solutions.

RTX-GRT7039-pipeline

To Know More About This Report, Request a Free Sample Copy

MARKET POTENTIAL & POSITIONING

RTX-GRT7039 (resiniferatoxin; RTX) is set to make a significant impact on the osteoarthritis treatment market, especially in knee pain management. As a powerful TRPV1 receptor agonist, RTX offers prolonged pain relief by deactivating the peripheral terminals of C- and A-delta nerve fibers. Currently undergoing Phase III clinical trials, RTX is expected to have data readouts in the latter half of 2024, with potential market authorization in the EU, US, and Japan by 2025/2026.

In May 2023, Grünenthal announced that RTX received Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration. This designation highlights RTX’s therapeutic potential as a non-opioid alternative for managing osteoarthritis pain. The designation, awarded based on promising Phase I and II data showing substantial pain relief and a favorable safety profile, expedites the drug’s development and regulatory review.

INKWOOD RESEARCH OFFERS AN ANALYSIS OF SEVEN KEY MARKETS

  • United States
  • Germany
    • According to the International Trade Administration, Germany’s healthcare sector is a major economic driver, employing one in six people. This sector generates an economic footprint of approximately $883 billion, accounting for about 12 percent of Germany’s GDP. This substantial investment in healthcare reflects the country’s commitment to medical innovation and patient care, which is likely to increase the demand for osteoarthritis medications.
    • As Germany’s population continues to age, the prevalence of osteoarthritis is anticipated to increase, driving a greater demand for effective treatments. Given the substantial economic stake in healthcare, significant resources will be available to support the development, approval, and distribution of advanced osteoarthritis medications.
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

TABLE OF CONTENTS

  1. INTRODUCTION TO THE REPORT
  2. RTX-GRT7039 OVERVIEW
    1. PRODUCT DETAIL
    2. CLINICAL DEVELOPMENT
      1. CLINICAL STUDIES
      2. CLINICAL TRIALS INFORMATION
    3. OTHER DEVELOPMENTAL ACTIVITIES
    4. PRODUCT PROFILE
  3. COMPETITIVE LANDSCAPE 
    1. MARKETED THERAPIES
    2. LATE-STAGE EMERGING THERAPIES
  4. RTX-GRT7039 MARKET ASSESSMENT
    1. MARKET OUTLOOK OF RTX-GRT7039 IN OSTEOARTHRITIS
  5. 7 MAJOR MARKET’S ANALYSIS
    1. MARKET SIZE OF RTX-GRT7039 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
    2. 7 COUNTRY ANALYSIS
      1. MARKET SIZE OF RTX-GRT7039 IN UNITED STATES FOR OSTEOARTHRITIS
      2. MARKET SIZE OF RTX-GRT7039 IN GERMANY FOR OSTEOARTHRITIS
      3. MARKET SIZE OF RTX-GRT7039 IN FRANCE FOR OSTEOARTHRITIS
      4. MARKET SIZE OF RTX-GRT7039 IN ITALY FOR OSTEOARTHRITIS
      5. MARKET SIZE OF RTX-GRT7039 IN SPAIN FOR OSTEOARTHRITIS
      6. MARKET SIZE OF RTX-GRT7039 IN UNITED KINGDOM FOR OSTEOARTHRITIS
      7. MARKET SIZE OF RTX-GRT7039 IN JAPAN FOR OSTEOARTHRITIS
  6. SWOT ANALYSIS
  7. ANALYST PERSPECTIVE

LIST OF TABLES

TABLE 1: RTX-GRT7039, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 2: RTX-GRT7039, GENERAL DESCRIPTION

TABLE 3: MARKETED THERAPIES

TABLE 4: EMERGING THERAPIES

TABLE 5: RTX-GRT7039 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

TABLE 6: RTX-GRT7039 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

TABLE 7: RTX-GRT7039 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

TABLE 8: RTX-GRT7039 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

TABLE 9: RTX-GRT7039 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

TABLE 10: RTX-GRT7039 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

TABLE 11: RTX-GRT7039 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

TABLE 12: RTX-GRT7039 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

LIST OF FIGURES

FIGURE 1: RTX-GRT7039 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

FIGURE 2: RTX-GRT7039 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

FIGURE 3: RTX-GRT7039 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

FIGURE 4: RTX-GRT7039 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

FIGURE 5: RTX-GRT7039 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

FIGURE 6: RTX-GRT7039 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

FIGURE 7: RTX-GRT7039 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

FIGURE 8: RTX-GRT7039 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

FAQs

RTX-GRT7039 works by activating TRPV1-expressing neurons, which leads to the reversible defunctionalization of the peripheral terminals of C- and A-delta nerve fibers. This process results in prolonged pain relief, making it a promising treatment option for managing chronic osteoarthritis pain.

In May 2023, RTX-GRT7039 was awarded Breakthrough Therapy Designation (BTD) by the US FDA. This designation, granted due to encouraging Phase I and II data demonstrating substantial pain relief and a favorable safety profile, accelerates the drug’s development and review process.

RTX-GRT7039 is administered via intra-articular injection directly into the affected joint, specifically targeting the area of pain in patients with osteoarthritis of the knee.

Request Customization
Request Customization
Request free sample